AVIDITE
LIVE

Serial Number

97284741

Owner

Element Biosciences, Inc.

Attorney

Samantha C. Markley

Filing Date

Feb 25, 2022

Add to watchlist:

No watchlists yet
View on USPTO

AVIDITE Trademark

Serial Number: 97284741

AVIDITE is a trademark filed by Element Biosciences, Inc. on February 25, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Element Biosciences, Inc. (35 trademarks)

9880 Campus Point Drive, Suite 210
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

February 25, 2022

Registration Date

Not Registered

Published for Opposition

November 12, 2024

Goods & Services

Clinical diagnostic instruments for medical use, namely, nucleic acid sequencers, imaging devices and analyzers

Medical diagnostic reagents; clinical medical diagnostic reagents; reagent kits and reagent beads with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical medical diagnostic purposes; reagents and reagent kits comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for diagnostic medical use and for clinical medical diagnostic use

Providing temporary use of online non-downloadable computer software and non-downloadable electronic data files for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, all the foregoing for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; providing temporary use of online non-downloadable computer software for data collection, management, and analysis of genetic information for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes

Computer systems, namely, computer hardware, downloadable computer software and associated downloadable electronic data files for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, all the foregoing for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; downloadable computer software for data collection, management, and analysis of genetic information for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; clinical diagnostic instruments for scientific use, namely, nucleic acid sequencers, imaging devices and analyzers

Assays and reagents for use in genetic research; diagnostic reagents for scientific or research use; diagnostic reagents for clinical or medical laboratory use; reagents and reagent kits comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for scientific research use, for diagnostic scientific use, and for clinical laboratory research use; clinical diagnostic reagents for laboratory use; reagent kits and reagent beads with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical diagnostic laboratory purposes

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 20, 2025 EXRA
SOU EXTENSION 2 GRANTED
Dec 19, 2025 EX2G
SOU EXTENSION 2 FILED
Dec 19, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 19, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 18, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jun 18, 2025 EX1G
SOU EXTENSION 1 FILED
Jun 17, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 17, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 24, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 12, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 12, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 23, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 3, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 23, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 23, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 21, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 21, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 21, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 19, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 19, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 10, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 10, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 19, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 19, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 19, 2024 CNRT
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 22, 2023 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 13, 2023 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 1, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 1, 2022 GNSL
SUSPENSION LETTER WRITTEN
Oct 1, 2022 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 10, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 9, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 9, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 14, 2022 GNRN
NON-FINAL ACTION E-MAILED
Mar 14, 2022 GNRT
NON-FINAL ACTION WRITTEN
Mar 14, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 7, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 2, 2022 NWOS
NEW APPLICATION ENTERED
Mar 1, 2022 NWAP